Neurogene (NGNE) has issued an announcement.
Neurogene Inc. has announced enhancements to their ongoing Phase 1/2 gene therapy clinical trial for NGN-401, targeting Rett syndrome in female pediatric patients. The company aims to speed up patient enrollment for the trial. Additionally, they’ve updated their corporate presentation online, reflecting these developments. This information, while made public, is not considered filed under the Securities Exchange Act nor incorporated by reference into the company’s Securities Act filings.
For an in-depth examination of NGNE stock, go to TipRanks’ Stock Analysis page.
